- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04357756
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial will have a run-in phase to explore the safety and tolerability of YH001 as a single agent for 21 days as DLT observation period then followed by a combination phase to further explore the safety and tolerability of YH001 combined with Toripalimab (anti-PD-1 antibody) for each dose level during dose escalation.
The dose escalation will follow the traditional "3 + 3" dose escalation scheme. These subjects will be treated with YH001 and Toripalimab. YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G. Toripalimab will be administered by IV (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle. A single subject will be enrolled at Dose A as starting dose of YH001, and subsequent cohort will be expanded to include 3-6 subjects.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Blacktown Hospital, Blacktown Cancer and Haematology Centre
-
Kogarah, New South Wales, Australia, 2217
- St George private Hospital
-
-
Victoria
-
Frankston, Victoria, Australia, 3199
- Peninsula & South Eastern Haematology and Oncology Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, aged ≥ 18 years
- Have advanced histologically or cytologically confirmed solid tumor
- Have progressed on after treatment with standard therapies or intolerant of standard care
- At least 1 unidimensional measurable target lesion per RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1
- Have life expectancy of at least 12 weeks based on investigator's judgement
Exclusion Criteria:
- Treated with any investigational drug within 4 weeks prior to the fist dose of study drug
- Received any anticancer therapy less than 28 days prior to the first administration of study drug or within 5 half-lives of the therapy agent, whichever is shorter. Prior palliative radiotherapy to bone metastases ≤ 2 weeks prior to the first dose of YH001 is acceptable
- Subjects with prior anti-CTLA-4 checkpoint inhibitors should be excluded
- Subjects with prior PD-1/L1 treatment intolerate to PD-1/L1 therapy should be excluded
- Subjects with a history of ≥ Grade 3 immune-related adverse events (AEs) resulted from previous immunotherapy or an AE of any grade that resulted in discontinuation of prior immunotherapy
- Subjects with a history of ≥ Grade 2 pneumonitis resulted from previous immunotherapy or with a SpO2 by pulse oximetry < 92% at the screening
- Subjects requiring systemic treatment with corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medications within 21 days before the planned first dose of study drug or has need to be treated while on trial. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease. Ophthalmologic, nasal and intra-articular injections of steroids are allowed
- Subjects with concomitant active autoimmune disease, history of autoimmune disease requiring systemic treatment, or history of autoimmune disease within the two years prior to study entry. Exceptions are subjects with vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus or hypothyroidism which can be managed by replacement therapy
- Primary central nervous system (CNS) malignancies or symptomatic CNS metastases. But subjects with asymptomatic CNS metastases might be eligible if they have no clinical evidence of progression since completion of CNS-directed therapy, minimum 4 weeks between completion of radiotherapy and the first dose of YH001 and are currently not receiving corticosteroids
- QTc > 450 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome
- Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to ≤ Grade 1 per CTCAE v5.0, except alopecia, < Grade 2 sensory neuropathy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: YH001 combined with Toripalimab
All the patients will receive YH001 intravenously as single agent for 21 days followed by combination phase.
|
YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.
Toripalimab will be administered by intravenously (Q3W) by the fixed dose of 240 mg from the 2nd cycle to 5th cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events and serious adverse events
Time Frame: From screening up to 1 year
|
The safety profile of YH001 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
|
From screening up to 1 year
|
Maximum tolerated dose (MTD)
Time Frame: During Cycle 1 (each cycle is 21 days)
|
MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle
|
During Cycle 1 (each cycle is 21 days)
|
Dose-limiting toxicities (DLT)
Time Frame: During Cycle 1 (each cycle is 21 days)
|
DLT is defined as a toxicity (adverse event at least possibly related to YH001) occurring during the DLT observation period (the initial 21 days) both in run-in phase of YH001 as single agent and in combination phase of YH001 in combination with Toripalimab
|
During Cycle 1 (each cycle is 21 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the serum concentration versus time curve within one dosing interval (AUCtau)
Time Frame: Up to 1 year
|
To determine the PK profile of YH001 alone and in combination with Toripalimab
|
Up to 1 year
|
Steady state AUC
Time Frame: Up to 1 year
|
To determine the PK profile of YH001 alone and in combination with Toripalimab
|
Up to 1 year
|
Maximum serum concentration (Cmax)
Time Frame: Up to 1 year
|
To determine the PK profile of YH001 alone and in combination with Toripalimab
|
Up to 1 year
|
Trough concentration before the next dose is administered (Ctrough)
Time Frame: Up to 1 year
|
To determine the PK profile of YH001 alone and in combination with Toripalimab
|
Up to 1 year
|
Time to reach maximum serum concentration (Tmax)
Time Frame: Up to 1 year
|
To determine the PK profile of YH001 alone and in combination with Toripalimab
|
Up to 1 year
|
Clearance (CL)
Time Frame: Up to 1 year
|
To determine the PK profile of YH001 alone and in combination with Toripalimab
|
Up to 1 year
|
Volume of distribution (Vd)
Time Frame: Up to 1 year
|
To determine the PK profile of YH001 alone and in combination with Toripalimab
|
Up to 1 year
|
Terminal half-life (T1/2)
Time Frame: Up to 1 year
|
To determine the PK profile of YH001 alone and in combination with Toripalimab
|
Up to 1 year
|
Dose proportionality
Time Frame: Up to 1 year
|
To determine the PK profile of YH001 alone and in combination with Toripalimab
|
Up to 1 year
|
Incidence of anti-drug antibodies (ADAs)
Time Frame: Up to 1 year
|
To assess the immunogenicity of YH001 in combination with Toripalimab
|
Up to 1 year
|
Incidence of neutralizing antibodies (NAbs)
Time Frame: Up to 1 year
|
To assess the immunogenicity of YH001 in combination with Toripalimab
|
Up to 1 year
|
Objective response rate (ORR)
Time Frame: Up to 1 year
|
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
|
Up to 1 year
|
Duration of response (DOR)
Time Frame: Up to 1 year
|
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
|
Up to 1 year
|
Time to response (TTR)
Time Frame: Up to 1 year
|
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
|
Up to 1 year
|
Progression free survival (PFS)
Time Frame: Up to 1 year
|
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
|
Up to 1 year
|
Overall survival (OS)
Time Frame: Up to 1 year
|
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
|
Up to 1 year
|
Disease control rate (DCR)
Time Frame: Up to 1 year
|
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
|
Up to 1 year
|
Duration of disease control (DDC)
Time Frame: Up to 1 year
|
To assess the preliminary antitumor activity of YH001 in combination with Toripalimab
|
Up to 1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YH001002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on YH001
-
Eucure (Beijing) Biopharma Co., LtdRecruitingAdvanced Solid TumorChina, Australia
-
Eucure (Beijing) Biopharma Co., LtdWithdrawnHCC | NSCLC Stage IV | NSCLC Stage IIIBChina, Australia, Taiwan, Armenia, Austria
-
Eucure (Beijing) Biopharma Co., LtdCompleted
-
Eucure (Beijing) Biopharma Co., LtdRecruiting
-
Tracon Pharmaceuticals Inc.Active, not recruitingSoft Tissue Sarcoma | Advanced Sarcoma | Metastatic SarcomaUnited States